Uneek Mehra - 10 Mar 2026 Form 4 Insider Report for BridgeBio Oncology Therapeutics, Inc. (BBOT)

Reporting relationship: Chief Financial Officer
Issuer ticker: BBOT
Reported as of: 10 Mar 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 12 Mar 2026, 16:58:25 UTC
Prior SEC filing: 28 Aug 2025
Next SEC filing: 05 May 2026
Source filing: View source filing
Reporting owner signature: /s/ Uneek Mehra

Key filing fact

Uneek Mehra filed Form 4 for BridgeBio Oncology Therapeutics, Inc. (BBOT) on 12 Mar 2026.

Key facts

This page summarizes Uneek Mehra's Form 4 filing for BridgeBio Oncology Therapeutics, Inc. (BBOT).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 12 Mar 2026, 16:58.

Change

Previous filing in this sequence was filed on 28 Aug 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001881504 Primary reporting owner

Mehra Uneek

Relationship: Chief Financial Officer
Address: BRIDGEBIO ONCOLOGY THERAPEUTICS, INC., 256 EAST GRAND AVENUE, SUITE 104, SOUTH SAN FRANCISCO
Signature: /s/ Uneek Mehra
Signature date: 12 Mar 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

BBOT transaction

Common Stock

Award

Transaction value
Shares: +23,330
Change %
Price: $0.000000^*
Shares after: 23,330
Date: 10 Mar 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

BBOT transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +105,000
Change %
Price: $0.000000^*
Shares after: 105,000
Date: 10 Mar 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 105,000
Exercise price: $10.19
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Represents a grant of restricted stock units ("RSUs"), each representing a contingent right to receive one share of the Issuer's Common Stock. The RSUs vest in 16 equal quarterly installments over a period of four years from January 1, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date. The RSUs will be settled in shares of Common Stock upon vesting.

Footnote F2

1/48th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of January 1, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date.